CD8A and cancer: Interleukin (IL)-15, a priority agent for cancer therapy,5 has been explored to improve the efficacy of vaccines, chemotherapies and adoptive T cell transfer approaches due to its ability to support DC, B cell, T cell and NK cell functionality, and to rescue tolerant or dysfunctional CD8+ T cells.6-12